


TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY DOCKET NO. P08898US00/BAS
		US APPL. NO. (If known, see 37CFR 1.5) 10/573,804
INTERNATIONAL APPLICATION NO. PCT/IB04/03146	INTERNATIONAL FILING DATE 28 September 2004	PRIORITY DATE CLAIMED 29 September 2003
TITLE OF INVENTION: IDENTIFICATION OF POLYMORPHISMS IN THE EPCR GENE ASSOCIATED WITH...		
APPLICANT(S) FOR DO/EO/US: AIACH		
Applicant herewith submits to the US Designated/Elected Office (DO/EO/US) the following items and other information:		
<input type="checkbox"/> 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 USC 371. <input type="checkbox"/> 3. This is an express request to begin national examination procedures (35 USC 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. <input type="checkbox"/> 4. The US has been elected (Article 31). <input type="checkbox"/> 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) <input type="checkbox"/> a. is attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> b. has been communicated by the International Bureau <input type="checkbox"/> c. is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> 6. An English translation of the International Application as filed (35 U.S.C. 371(c)(2)). <input type="checkbox"/> a. is attached hereto. <input type="checkbox"/> b. has been previously submitted under 35 U.S.C. 154(d)(4). <input type="checkbox"/> c. is not needed since the International Application is in English. <input type="checkbox"/> 7. Amendments to the claims of the International Appln. under PCT Article 19 (35 USC 371 (c)(3)) <input type="checkbox"/> a. are attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> b. have been communicated by the International Bureau. <input type="checkbox"/> c. have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> d. have not been made and will not be made. <input type="checkbox"/> 8. An English translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> 10. An English translation of the annexes to the Int'l Pre. Exam. Report under PCT Article 36 (35 USC 371(c)(5)). Items 11. to 20. below concern document(s) or information included: <input checked="" type="checkbox"/> 11. An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. <input type="checkbox"/> 12. An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 & 3.31 is included. <input checked="" type="checkbox"/> 13. A preliminary amendment. <input type="checkbox"/> 14. An Application Data Sheet under 37 CFR 1.76. <input type="checkbox"/> 15. A substitute specification. <input type="checkbox"/> 16. A power of attorney and/or change of address letter. <input checked="" type="checkbox"/> 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 & 37 CFR 1.821-825. <input type="checkbox"/> 18. A second copy of the published international application under 35 USC 154(d)(4). <input type="checkbox"/> 19. A second copy of the English translation of the international application under 35 USC 154(d)(4). 20. Other items or information: <input type="checkbox"/> Return Receipt Postcard. <input checked="" type="checkbox"/> A copy of the Notification of Missing Requirements under 35 U.S.C. 371. <input checked="" type="checkbox"/> In the event that a petition for extension of time is required to be submitted herewith, and in the event that a separate petition does not accompany this response, applicant hereby petitions under 37 CFR 1.136(a) for an extension of time of as many months as are required to render this submission timely. Any fee is authorized in 21(c). <input type="checkbox"/>		

COPY

U.S. APPLICATION NO. <i>(if known)</i> 10/573,804		INTERNATIONAL APPLICATION NO. PCT/IB04/03146		ATTORNEY DOCKET NO. P08898US00/BAS	
The following fees have been submitted:				CALCULATIONS	PTO USE ONLY
<input type="checkbox"/> 21. Basic national fee (37 CFR 1.492(a))				\$300	\$
<input type="checkbox"/> 22. Examination fee (37 CFR 1.492(c))					
<input type="checkbox"/> Written Opinion or IPER by US indicates all claims satisfy PCT Art. 33(1-4)				\$0	\$
<input type="checkbox"/> All other situations				\$200	
<input type="checkbox"/> 23. Search fee					
<input type="checkbox"/> Written Opinion or IPER by US indicates all claims satisfy PCT Art. 33(1-4)				\$0	\$
<input type="checkbox"/> Has been paid on the Int'l Appln. to the USPTO as ISA				\$100	
<input type="checkbox"/> International Search Report prepared and provided to the Office				\$400	
<input type="checkbox"/> All other situations				\$500	
TOTAL OF 21, 22 AND 23				\$	
<input type="checkbox"/> SIZE FEE: sheets - 100 = + 50 = <i>(rounded up)</i> × \$250 =				\$	
<input type="checkbox"/> Surcharge of \$130 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e))				\$130	\$130
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	11 - 20 =	0	X \$50 =	\$0	
Independent Claims	3 - 03 =	0	X \$200 =	\$0	
<input type="checkbox"/> Multiple Dependent Claim(s) (if applicable)			+ \$360 =	\$	
TOTAL OF ABOVE CALCULATIONS =				\$130	
<input type="checkbox"/> Applicant claims small entity status - 37 CFR 1.27. Fees above reduced by ½.				\$	
SUBTOTAL =				\$130	
<input checked="" type="checkbox"/> Fee for Extension of Time				\$120	
TOTAL NATIONAL FEE =				\$	
<input type="checkbox"/> Fee for recording enclosed assignment (37 CFR 1.21(h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) \$40 per property				\$	
TOTAL FEES ENCLOSED =				\$250	
Amount to be				Refunded	\$
				Charged	\$
<input checked="" type="checkbox"/> Payment of \$250 is made by attached Credit Card Payment Form (PTO-2038) <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required for this submission (except claims fees if the box below is checked) or credit any overpayment to Deposit Account No. 12-0555. <input type="checkbox"/> Do not charge any claim fees now - any additional claims fees will be paid with the Missing Requirements.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
POWER OF ATTORNEY & CORRESPONDENCE ADDRESS: CUSTOMER NO. 00881			NAME: B. Aaron Schulman REG. NO.: 31,877 Signed (for) by:  REG. NO.: 31,877		
Date: May 21, 2007					

**PETITION FOR
EXTENSION OF TIME
UNDER 37 CFR 1.136(a)**

Application #	10/573,804
Confirmation #	9377
Filing Date	March 28, 2006
First Inventor	AlACH
Art Unit	
Examiner	
Docket #	P08898US00/BAS

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and fee under 37 CFR 1.17(a) are as follows.

☐ NOTE: Applicant claims small entity status.

COPY

No extension of time previously obtained.

<u>Time Period</u>	<u>Large Entity Fee</u>	<u>Small Entity Fee</u>
<input checked="" type="checkbox"/> One month	<input checked="" type="checkbox"/> \$ 120	<input type="checkbox"/> \$ 60
<input type="checkbox"/> Two months	<input type="checkbox"/> \$ 450	<input type="checkbox"/> \$ 225
<input type="checkbox"/> Three months	<input type="checkbox"/> \$ 1020	<input type="checkbox"/> \$ 510
<input type="checkbox"/> Four months	<input type="checkbox"/> \$ 1590	<input type="checkbox"/> \$ 795
<input type="checkbox"/> Five months	<input type="checkbox"/> \$ 2160	<input type="checkbox"/> \$ 1080

☒ Payment by credit card. FORM PTO-2038 in the amount of \$250 is attached.

☒ The Director is authorized to charge any fee or additional fee due in connection herewith to Deposit Account No. 12-0555:

- (1) if no payment or an insufficient payment is enclosed and a fee is due in connection herewith; or
- (2) if a further fee and petition for extension of time are required at this time - and in this event, applicant hereby petitions under 37 CFR 1.136(a) for any further extension of time of as many months as are required to render this submission timely.

Date: May 21, 2007

05/23/2007 MKAYPASH 00000020 10573804

02 FC:1251

120.00 00

Signed By
Attorney of Record

Name: B. Aaron Schulman
Registration No.: 31,877

STITES & HARBISON PLLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314
TEL: 703-739-4900 • FAX: 703-739-9577 • CUSTOMER NO. 00881

<p style="text-align: center;">PRELIMINARY AMENDMENT</p>	Application #	10/573,804
	Confirmation #	9377
	Filing Date	03/28/06
	First Inventor	AIACH
	Art Unit	
	Examiner	
	Docket #	P08898US00/BAS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COPY

S I R:

Prior to examination

A) please consider the responsive **Remarks and Statement** provided herewith in


Attachment A; and

B) please amend the above identified application as follows:

- After page 29, please insert the **attached sequence listing** and substitute this listing for the one originally filed.
- A **Computer Readable Form** of the sequence listing is also provided.
- **Amendments to the Claims** are reflected in the listing of the claims provided herewith in **Attachment B**.

In view of the amendments made and the remarks provided, it is submitted that the present application is now in condition for examination and allowance.

Respectfully submitted,



By: B. Aaron Schulman
Registration No.: 31,877

Date: May 21, 2007

STITES & HARBISON PLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314
TEL: 703-739-4900 • FAX: 703-739-9577 • CUSTOMER NO. 000881

ATTACHMENT A

REMARKS

By the present amendment, a sequence listing and diskette in suitable US form are now provided. Applicants state as follows:

STATEMENT

Applicants state in accordance with 37 C.F.R. § 1.821(f) that the content of the enclosed paper sequence listing and computer readable form are the same, and that in accordance with 37 C.F.R. § 1.821(g), the enclosed submission contains no new matter.

Applicants submit that this application is now in compliance with sequence listing requirements. The claims have also been amended to eliminate multiple dependencies.

Accordingly, Applicants submit that the present application is now in condition for examination and allowance.

END OF REMARKS

 COPY

ATTACHMENT B
Amendments to the Claims

COPY

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Original) An *in vitro* method for determining the risk of developing thrombosis in a subject, which method comprises identifying polymorphisms of EPCR gene on at least one of positions 1651, 3610, 4216, and 6936 (SEQ 10 NO:1), wherein the presence of G at position 1651, C at position 3610, A at position 4216, or G at position 6936 is indicative of a higher risk to develop thrombosis in comparison with a control subject that does not show the same polymorphisms.

2. (Original) An *in vitro* method according to claim 1, which method comprises identifying polymorphisms of EPCR gene at positions 1651, 3610, 4216, 6936, 3787, 3877, 4868, 5233, 5760, 6333, 7014, 7968, 7999 of SEQ 10 NO: 1, wherein the simultaneous presence of :

- G at position 1651
- C at position 3610
- A at position 4216
- G at position 6936
- C at position 3787
- G at position 3877
- T at position 4868
- G at position 5233
- T at position 5760

- T at position 6333
- G at position 7014
- A at position 7968
- G at position 7999

A stylized, hand-drawn style stamp that says "COPY" in capital letters. The letter "C" is enclosed in a small square box.

are designated A3 haplotype and, when present on at least one allele, are indicative of a higher risk to develop thrombosis in comparison with a control subject without any A3 allele.

3. (Currently Amended) The method according to claim 1-~~or~~2, wherein said thrombosis is a venous thrombosis.

4. (Currently Amended) The method according to ~~any of~~ claims 1-3, wherein the analysis is undertaken on genomic DNA that is extracted from a biological sample of the subject.

5. (Currently Amended) The method according to ~~any of~~ claims 1-4, wherein the analysis comprises a step of amplification of the genomic DNA.

6. (Currently Amended) The method according to ~~any of~~ claims 1-5, wherein the polymorphisms of the EPCR gene are identified by sequencing.

7. (Currently Amended) The method according to ~~any of~~ claims 1-6, wherein at least one of the polymorphisms of the EPCR gene is identified by RFLP analysis.

8. (Original) The method according to claim 7, comprising identifying the polymorphism of EPCR gene on position 6936, by creating a restriction site for endonuclease PstI by amplification of the EPCR gene with mutagenic primers, when the amplified fragment contains an A at position 6936, so that when the amplified fragment containing a G, it remains undigested.
9. (Original) An isolated nucleic acid encoding the EPCR receptor, that comprises SEQ ID NO:2.
10. (Currently Amended) A kit suitable for the methods according to ~~any of~~ claims 1 to 6, which kit comprises a pair of nucleotide primers specific for amplifying all or part of the EPCR gene comprising at least one of positions 1651,3610,4216 of SEQ ID NO:1.
11. (Original) A method for genotyping the EPCR gene, which method comprises identifying the polymorphism of the EPCR gene at position 4216 (SEQ ID NO: 1), wherein the presence of C at position 4216 shows the A1 haplotype, the presence of G at position 4216 shows the A2 haplotype, and the presence of A shows the A3 haplotype.

SEQUENCE LISTING

COPY

<110> AIACH et al.

<120> Identification of polymorphisms in the EPCR gene
associated with thrombotic risk

<130> P08899US00/BAS

<140> 10/573,804

<141> 2006-03-28

<160> 18

<170> PatentIn Ver. 2.1

<210> 1

<211> 8167

<212> DNA

<213> Homo sapiens

<400> 1

```

aaatgaaata tttcaggctg tgcacagtgg ctcaggcttg taatcccagc atgtttgggag 60
gctgaagtgg gcggatcacc tgaggctcagg agtttgagac caacctggcc aacatggtga 120
aatcccatct ctactaaaaa tacaaaaatt agccagggtg ggtggcagggt gactgtaatc 180
ccagctactt gggaggctga gcaggagaa tcgcttgaat ctggggagggt gaggttgacg 240
tgagccgaga tcaaggccact gcatacagca agactccatc tcaaaaaaaa gaaaaaaaaa 300
aagaaaaaag aaatgtttca taatttttaa taaaaggcaa gacaataaa attggtagtt 360
atttaagtca ttctactttt cctgaggccc agtgaggaa acaaaagttc ctatccttgt 420
tccaaactaga ccattttgat aagctgcaaa aagaaaagac ttgatgcta ttctctagcc 480
agtttgcacg agctgagagg tgagcatgga agctcttgca tatatttcagt tcagagaatg 540
ggtgcttagt ttatgtccag agtttgcctc agatttcact atgacgtcag ctctccgggg 600
agaagtatat aaaataaaaa gttaaaatcc ctctcagtc ttaccacat cctattcccc 660
agaggtaatc tctattgaca gtaccctccc agatattttc cctatgtata tacaataaca 720
cagatcacaca ctgaaagtta attttggcca ggtgcagttg ctctgcctta taccagagga 780
ttgcttgagt gcaggagttc aagaccagcc tggggcaaat agcgagacca catctctagt 840
aaaaataaaa aaaaaatagc taggcgtgggt ggcacagtgg cagctacctt tagtctcagc 900
taactcgggtg gttgagggtg gagaatcact tgagcccggt aggtcaagct tacaatttagc 960
tgtgattgct tcactgcact atagcctggg caacagagct agaccctgtc tcaaaaaaat 1020
aataaataatt tttatatata tatatgagga tgaatttaca tgattattat ttgaacagaa 1080
gtgaaactct tctctttttt ttttcagaca gaactctgcc gcatgaccca gctagaatg 1140
cagtggtgtg atctcgcccc tctgcaacct ccacctccca ggttcaaggc attctcatgc 1200
ctcgctctcc caagttagtg ggattacagg catgcaccac atgcccagc taatttttgt 1260
atttttcgta gagacgttgt ccatattggc caggctggtc tcaaaactct ggctcgaagt 1320
gatctgcacca cctcgccctc ccaaagtggc agcagcatgc tcggaggagt gactttaaag 1380
cttttctact tgcttctagc agtaaggagc gcattttaca ctgctatcca aaactcatca 1440
tagaaaacata cacacacaaa accaaagcac acatatacaa ctgagcaaat atttcatgac 1500
ataacacatt ctcttactaa ggggtgacgcg ctgaaatttt gtattctgtc ctatttcaat 1560
ttttaaaatt ggtaaccatg acctgctaaa ttgatttcat tgtccactaa taaattatga 1620
ctcaggtttc aaaaagattg ctttaggtaa ccaatcatct ttgcagatt atacagattg 1680
ctcataattt tctctatttt tttaaaaaca tgctgcagtg aactgctttt caactcaatt 1740
atgactactt ctgagaccaa gatcccgagt tatgtaattg ttatttactt aaaaattctgg 1800
taaaatgtag ccatttactt ggaaaactaa attttaatct tggattctgc accaccatga 1860
tatataaaat ttgtggcaagt cctcgacact ctctggacct caactctccc atcagcaacc 1920
tgctgatcct actccagga gtgtgctcta agttgaaagt agatgcccc cccctcgagt 1980
cagcgccggc aggaacttct accaagccct tctcccctct tctcgctccc tgttctctgt 2040
tcttaggaag cagcccaagg agaagggaag aggcagggtc gggcaggagg gagcaatgaa 2100
ggcgccggga gagggagggc agggaggagg ccggccctct agtaggaat gagacacagt 2160
agaataaaca ctttataagc ctcttctctc tccatctctc tggcctctct ccatctctct 2220
ctgcccagac tccgcccctc ccagacggtc ctcacttctc ttttccctag actgcagcca 2280
cgggagccgc gaggccggcc gcggcaggaa gagggtccg gagcctcaac ttcaggatgt 2340

```

tgacaacatt	gctgccgata	ctgctgctgt	ctggctgggc	ctttgttagc	caagacgcct	2400
cagatgggtg	ctggggggca	catctcctgc	ctcaggatgg	ttctggagaa	tctcagttca	2460
tctgggcaca	tgccaagacc	acaggagagc	ttatctcaca	gtcagctgtg	ctgcagctgtg	2520
ctagatctct	ctacaggcca	ggcagagtct	tggggactgg	ttcgtgtccc	aaagcccaagg	2580
tgagttagta	catttaagcc	cctgaaaagg	gggagatgaa	agaggtctagg	ggaaacaggga	2640
tgactggaaa	catgagaagg	aaaccagcag	agagggtagg	agaactcagcc	ccaggggagag	2700
gggagcaagg	gggaactagg	gtgatggtag	ataggggtac	atctagagctg	gacgggaaga	2760
ggctcagaag	agaagagaaa	tggagggaa	gggaagacc	tgggaaaaat	gatgggaagaa	2820
tggggggagg	agtggggcag	agagaggtta	ggggaggtta	gggaaaaatg	aaggagagctg	2880
gtcgagcgtg	gtggaaactg	ggagaaaagg	atgctgtgcc	tataagaact	tatgggagat	2940
caggctctgc	aagtgggcct	gtttaagcag	aaaaggaggt	tattaccctc	cattataatt	3000
gcacaggggc	ctctcttccc	ctctctcaca	atccccgtaa	cttcagttct	ccctcagcag	3060
aggcagcaaa	taataaccag	tattcaatga	gtgctcacta	tggttaatac	atgtattgac	3120
ccatttaact	tgacaaaacc	cctaaagggt	ggtaataatta	ttactatctc	cattttatga	3180
ggagaaaact	gggtcacaga	gtagttaagg	accatgtcta	gggttatcca	taaataatac	3240
tattccatc	tgcgacatca	aagcacaa	tctcaaatgc	aaacacagag	aggaccccat	3300
cacacacaca	gattttaca	cccggaactc	tccaatgtg	ctctgggcat	caactctgtg	3360
ccagcctctt	tctggggtgt	aggaagcaga	gattaccaag	catggttcca	tgccttagag	3420
gagtcagagt	tggcctgtgt	gtgtttggag	acagccaggt	agtattccgt	gagatacaca	3480
ctaatatatt	gtggctctgg	atcactgaaa	cagacacact	gtgtctctgt	gggcatcaga	3540
aaaaaatttc	caagaagagg	gcaactgagc	tgggtctttt	ttctctttgt	ttctctttct	3600
ttttcttttt	tttttttttt	tttttttttt	agatggagtc	ttgtgctgtc	accagggctg	3660
gaatgcagtg	gcacaatttc	agctaaactgt	aacctccaac	tcccaggttc	aggcgattct	3720
ctgcctcagc	cctcctgagt	agctgggact	acaggcatgt	accaccacgc	ctggcttaata	3780
tttgtacttt	tgatagacat	ggggtttcgc	catgttgccc	aggctggctc	tgaatccctg	3840
acctcaagtg	atccgcggcg	ctcgccctcc	caaagtgtct	ggattacagg	catgagccac	3900
cgccggccagt	ctctgagctg	ggtctttaat	catgaataaa	ccttcgcaag	gagaaaaagg	3960
gaggcagagc	aatcctgaca	tgctattcat	gtgtcagcca	aaggcagcat	gaggaaatccc	4020
aactagtttg	atatataaag	agcgggaagc	ggccagaaaa	ggcagcaggg	gccaggtctc	4080
tagcagcctt	gaatgccagg	ctaaagactc	tggacttgat	cctgtgggga	ggcagtgtag	4140
cagaatggct	gaagtctgga	cttgactgcc	tacgtgcaaa	ccttggtctc	gctacactat	4200
ctctgtctca	ttctgcctat	tagactgggg	tataataag	tagctattgc	ataagccac	4260
tggggaaaag	cacaaagact	ataatgtatg	taaaagccat	tgcccaggtt	ataatacga	4320
ctgagatcac	gttgctctat	attatttttg	attaatgaag	gggagggggt	tatggcaactg	4380
gaagatttta	agttagaaaa	ggacatgac	tcatcctctg	gtcaggttga	ggtcggaata	4440
gagaaagggg	agatgaagta	gaaagttact	accocagctc	agatgagacg	gatgaatcct	4500
gaatcagggc	agtgggaagg	gagatggaga	acaggcgatg	gaattggaat	ttatttcagg	4560
tcaggatttg	ttaccacttt	gttccgttgg	ttaacagga	acgggggggg	ggagagccga	4620
gggtgaaaaa	ggaggcgaaa	aggaggtgtc	cttccactgc	aggcctcagt	ttcctcatct	4680
gtaaaaocga	gataataatc	cctgtcctgt	cctcctggca	gagttactgt	cagcgtcaaa	4740
cgggagaagg	ggtgggaggg	cacatataag	tttatgaaag	gtcgagaagg	ggcgaggcca	4800
gcctcagagt	aggggggtat	tatcttcgcg	tgcccggcgc	cccctccacc	ggccggccag	4860
gctgaagtgt	actctgcgcg	caggctccca	aagacttcac	atgtctccac	tctctcaatt	4920
ccgcgcacc	tatcacgtgt	ggtaaccagg	caacgcgtcg	ctggggggag	acctcaagca	4980
cgctgctgaa	ggccagacga	catcatcgag	gtcagccctc	ctgcagccctg	tgcaggagcc	5040
cgagagctgg	gcgcgcacgc	agagtggcct	cgagtcctac	ctgtccactg	tccagggcct	5100
cgctgcgcct	gtgcaccagg	agcggacctt	ggcctgtgag	tagcgcgcga	cgctggggcg	5160
ggtctggggc	gggctagtgg	ggggggggcc	tggcgggtgg	ggggcggggc	tggcggtatg	5220
aggcggcgtg	gggcttgcag	ggaccocgga	gccactgga	ctcggtggcg	ctcggtccctt	5280
tgaagattgc	tgggtggggg	ctggagagag	cgatgtgtcc	ccgctaagaa	agccccgact	5340
cggggcggtg	tctctgtcgc	ataacctctt	gggatagacc	ctgttggaag	ccctctgacac	5400
cgtgagctcg	aaggtcccca	gaaaactcct	caccctctgc	ctcacagtcc	tcccaactct	5460
tttcttcata	gatctccgtc	cttcccttcc	cacagccccc	agcactctac	ccccaccctc	5520
ccagocctac	ctcatacaag	ctgatgactt	gcctcttagc	tcactcatct	accgaactcc	5580
ttcccccaaa	gaccccaagt	tcttctctca	aagccccact	ccttccccgt	cacaaccctca	5640
actcctctctt	ctcaagacc	ccaatttctt	ttctcaaaag	accaagcacc	actcgtctcc	5700
ccttccccca	ccatcatggc	ctttaattcc	tttctctctc	agtcccccac	cccacccctc	5760
tttttttttt	tttttttgag	cttggtgtct	acggagtctt	gtcgtgtgtt	ccaggttgga	5820
gtgcagtggc	gcgatctcgg	ctcactgcaa	cttccgcctc	ccgggttcaa	gcgatctccc	5880
tgctctcagg	tcccaagcag	ctgggactac	aggccaccgc	caccacgccc	ggctaatttt	5940
ttgtattttt	agtagagacg	gggtttcgcc	atgttggcca	gctgggtctc	gaactccctga	6000

```

cctcaggcgca tccacaagcc tggcctccca aagtgetggg attacaggcg tgagctgccg 6060
ccccctgccc agcctcaccc cctgtttttt ttttctatta cagttgaaca aggcctgaca 6120
attccctttt tccatcacag tcccttgccc agcctctaac aggcctaacc 6180
caaacccctt ctcacagccc caggcccttc tcccatagtt tccctgacct agactcccc 6240
ctctccacag cactgactct tgcttctca ttttcttttc cctctggttg gctcgcccc 6300
acacctggca cctctctgct acagtccctt gatcctgact gctctatcac agtctctctg 6360
accatccgct gcttctctgg ctgtgagctg cctcccgagg gctctagacc cactgtcttc 6420
ttcgaagtgg tgcgtgaatg gagctccttt gtgagtttcc ggcgggagca agccttgtag 6480
caggcgagca cccaggtcac ctcgggagtg ctcgggagtg gtcaccttca cctgcagca 6540
tacaaccgca ctcggtaga actgcgggaa tctctggagg acacctgtgt gcagtagtg 6600
cagaacataa tttccgggga aaacacgaaa ggtatgatgg gacggggccc aggcctgcaa 6660
gctggggaga gggcggttcc cagacaaatg gatggacctg aaggatggat gcttagagca 6720
acaagaggcc cacagctggg ggtttgggac agaacacacg cagcttcagt cagttggtaa 6780
acgggtccct tctctctggg gcagaaacgc tttggggttt gactcaaatc atggactcct 6840
tgggggccta tcttctgggc taactctttg catgttctgc agggagocaa acaagccgct 6900
cctcacactc gctggtcctg ggcgtctctg tgggcagttt catcatttgt gcttggtctg 6960
taggcatctt cctgtgcaca ggtggaacgc gatgttaatt actctccagg cccgtcagaa 7020
ggggctggat tgaatggagg tggcaaggga aagtcttcagc tcacttgtaa ccagactccc 7080
ccaagtgaac caccagaagg tttgagatga cagctccttt cttctccacc atctgccacc 7140
tgaagatttg agggaggagg gatggagagg agaggtggac aaagtactgt gtttgctaa 7200
aacctaagaa cgtgtatgct ttgctgaatt agtctgataa gtaagtgttt atctatcttt 7260
gtggaaaaca gataatggag ttggggcagg aagcctatgg ccatcctccc aaagacagac 7320
agaatcacct gaggogttca aaagataaa ccaataaac aagtcatacc caatcaaaat 7380
acaacatcca atactccag gtgtgtcaga cttgggatgg gacgctgata taagtgggta 7440
gaaggaagta acagcaagaa gtggtgaaa tgtaaaaatc agtcataatg cagtgatca 7500
attattaatc aattaataat attaataaat tctctatatt taaggcatgt ttatctctc 7560
cactttgcga aatttctgga aaagtaacct ataccattt cttctgtctc ctattctctc 7620
actcatcttt tttttttttt tttttttttt ttgagacaga gtcctgtctc ttgctccagg 7680
ctggaagtga atggtgtgat ctcagctcac tgcaacctct gctcccgcct tcaagcaatt 7740
ctctgcctcc agcctcccaa gcagctggga ttacagatgc ttgccaccac acccagctaa 7800
tttttgtatt tttagtagag atgggggttc accacgttgg ccatcctgac cctgtagctc 7860
gcttccactc gccctcccaa gtgctgggat tagacgtgag ccaactgcgc ttgtctcttc 7920
actcatcttt agacccagtg caatctgact tctctataaa ctactctaa atcaccagta 7980
accttaattc gtcaaacctg caccctacat ggtatctgca aatttgcgca ctagaactct 8040
ctttttgctt taactctgca gataccaac ttcgaatttt aaaactgttc ttgctacttt 8100
ttttcaatcc ctttgatcat gtcattctac acgatttacc ctggaattgc tggcttcttt 8160
agaatttc

```

<210> 2
<211> 8167
<212> DNA
<213> Homo sapiens

```

<400> 2
aaatgaataa tttcaggctg tgcacagtgg ctcaggcttg taatccagc atgttgggag 60
gctgaagtgg gcggaacacc tgaggtcagg agtttgagac caactggcc aacatggga 120
aatccccact ctaactaaaaa tacaataaatt agccagggtg ggtggcagg gactgtaatc 180
ccagctactt gggaggctga gccaggagaa tgcgttgaat ctgggagtg gaggttgcag 240
tgagccgaga tcacgccact gcatacagca agactccatc tcaaaaaaaa gaaaaaaa 300
aagaaagaata aatgtttcca taatttttaa taaaaggcaa gacaataata attggtagt 360
atttaagtca tctacttttt cctgaggccc agtgcaaggaa acaaaagtcc ctatccttgt 420
tccaactaga ccaattttgat aagctgcaaa aagaaaagac ttgatgcta ttcttagcc 480
agttttgcaac agcttgaggg tgagcatgga agctcttgca tatattctc tagagagat 540
ggtgcttagt ttatgtccag agtttgtccc agatttcaat atgacgtcag ctctccggg 600
agaagtatat aaaaataaaa gttaaaatcc ctctcagtc agatattttc cctatgata 660
agaggttaat tctattgaca gtacccctcc agatattttc cctatgata tacaataca 720
cagatcacaca ctgaaaagtt attttgcca ggtgcagttg cctctgccta taccagagga 780
ttgcttgagt gcaggagttc aagaccagcc tgggcaacat agcgagacca catctctgt 840
aaaaataaaa aaaaataagc taggcgtggt ggcacagtgg cactgactc tagtctcag 900
tactcgggtg gttgaggtgg ggaatcact tgagccggg aggtcaacc tacaattagc 960

```

tgtgattgct	tactgcaact	atagcctggg	caacagagct	agaccctgtc	tcaaaaaaat	1020
aataataaat	tttataatata	tatatgagga	tgaattatca	tatgtattat	ttgaacagaa	1080
gtgaaatctt	tctctttttt	ttttcagaca	gaactctggc	gcatgaccca	ggctagaagt	1140
cagtggtgtg	atctcggccc	tctgcacact	ccacctccca	ggttcaagcg	attctcatgc	1200
ctcgctctcc	caagttagctg	ggattacagg	catgcaccac	catgccccag	taattttttg	1260
atttttctga	gagacgttcg	ccatattggc	caggctggtc	tcaaaactct	ggcctcaagt	1320
gatctgccca	ctcgccctcc	ccaaagtgcc	agcagcatgc	tccggaggagt	gaactttaaag	1380
cttttctact	tgcttctcag	agtaagggac	gcatttttaca	ctgctatcca	aaactcatca	1440
tagaaaacata	cacacacaaa	accaaagcac	acatatataa	ctgagcaaat	atttctatgac	1500
ctctactactt	ctcttactaa	gggtgacgcy	ctgaaatttt	gtattctgtc	ctattctactt	1560
ttttaaaaat	ggtaaacctag	acctgctaaa	tgtatttcat	tgctcaactaa	taaatattatga	1620
cctcagtttc	aaaaaagattg	ctttaggttaa	gcaatcatct	cttgagattt	tacagatattg	1680
ctcataaattc	tctctctattt	tttaaaaaaca	tgtctgacgtg	aactgcttta	caactatttt	1740
atgactactct	ctgagaccaa	gatcccgat	tatgtaattg	ttatttactt	aaaattctggy	1800
taaaatgtag	ccattatact	ggaaaactaa	atttttaact	tggatctgtc	accaccatga	1860
tatataaact	tgtggcaagt	ccctgcacct	ctctggacct	caatctcccc	atacgcaacc	1920
tgctgatctg	actcccagga	gtgtgctcta	agttgaaagt	agatgcccca	ccccctgagt	1980
cagcgccggc	aggactttct	accaagccct	tctccccctt	tctcctctcc	tggtctctgt	2040
tcctaggaag	cagcccaagg	agaagggaaa	aggcaggtct	gggcaggagg	gagcaatgaa	2100
ggcgggggca	gagggagggc	aggagggagg	ccggccccct	agtaggaat	gagacacagt	2160
agaaaataaca	ctttataagc	ctcttctctc	tccatctctc	tggtctctct	ctactctctc	2220
ctgccagagc	tcgcgccctc	ccagacggtc	ctcacttctc	ttttccctag	actgcagcca	2280
gcggagcccg	cagccggccc	gagccaggaa	cccaggtccg	gagcctcaac	tccagatgt	2340
tgacaacatt	gctgcggata	ctgctgctgt	ctggctgggc	cttttgtagc	caagcagcct	2400
cagatgttga	tctgggggca	catctcctgc	ctcaggatgg	tctcagtgaa	ctcagctcta	2460
tctggggcaca	tggcgaagcc	acaggagagc	ttatctcaca	gcactgtgtg	ctcgagctgt	2520
ctagatctct	ctcacaggga	ggcagagtct	tgtgggactgg	ttcgtgtccc	aaagccaagg	2580
tgagttagta	catttaagcc	cctgaaaagg	gggagatgaa	agaggtcagg	ggaaacagga	2640
tgactggaaa	catgagaaa	aaaccagcag	agagggtagg	agaactcagcc	ccaggggagag	2700
gggagaaaag	ggaactgagg	gtgatggtag	ataggggtga	atctagggga	gcagggaaga	2760
ggctcagaag	agaagagaaa	tggagggaa	gggaagacc	tgggaaaaat	gaggaagaaa	2820
gtgggggaag	agtgggcgag	agagaggtta	ggggaggcta	gggaaaaattg	agagagagct	2880
gtcgacactg	gtggaactgc	ggagaaagag	atgctgtgcc	taatagaact	tatgggcgat	2940
cagcgtctgc	aagtgccctc	gtttaagcag	aaaaggaggt	tattaccact	catattaatt	3000
gcacaggggc	ctcccttccc	ctctctcaca	atccccgtaa	cttcagctctc	ccccctcagag	3060
aggcagcaaa	taataaccag	tattcaatga	gtgctcacta	tggttaatac	atgtatttgc	3120
ccatttaact	tgcacaaacc	cctaagggtg	ggtaattatta	ttactactctc	ctatttatga	3180
ggaggaaaact	gggtccacaga	gtagttaagg	accatgtcta	gggttatcca	taaatatact	3240
tatttcacatc	tgcagataca	aagcacaaact	tctcaaatgc	aaacacagac	aggaccactc	3300
caacacacaa	gattttaca	cccggaactca	tccaaatgtg	ctctgggcag	caactctgtg	3360
ccagcctctt	ttctgggtgt	aggaagcaga	gattaccacag	catggttcca	tagcttagag	3420
gagtcagagt	tggcctgtgt	gtgtttggag	acagccaggt	agtatcccg	gagatcacaca	3480
ctaattatgt	gtggtctggg	atcactgaaa	cagacacact	gtgtctcgtg	gggcatcaga	3540
aaaaaatttc	caaggaaggg	gcaactgagc	tgggtctttt	ttcttttgc	ttctcttctc	3600
tttttttttc	tttttttttt	tttttttttt	agatggagtc	tttgcgtctc	accagagctg	3660
gaatgcagtg	gcacaatttc	agctaaactgt	aaectccaac	tcccaggttc	aggcgattct	3720
ctcgctcag	ctcctgagtg	agctgggact	acaggcatgt	accaccacgc	ctggctaata	3780
tttgtactat	tagtacagat	gggggttccg	catgttggcc	aggctggctc	tgaactccgt	3840
acctcaagtg	atccggccgc	ctcgccctcc	caaatgtcgt	ggattacgct	catgagccac	3900
cgcgccagtg	ctctgagctg	gggtcttaaat	catgaataaa	ctctgccagg	cagaaaaagg	3960
gaggcagagc	aaactctgaca	tgctattcat	gtgtcagcca	aaggcagcat	ggcgaatccc	4020
aactcagttg	atatataagc	agcggaagc	ggccagaaaa	ggcagcagcg	ggcaggtctc	4080
tagcagcctt	gaatgccagg	ctaaagactc	tggacttgat	cctgtggggg	ggcagtgtag	4140
cagaatggct	gagtgctgga	cttgactgcc	tacgtgcaaa	ctctggctctc	ctactactat	4200
ctctgtctca	gtttccacatg	tagactgggg	ttataataag	tagctattgc	attaagccac	4260
tggggaaaag	cacaaaagata	ataatgtatg	taaagcccat	tgccaggttt	ataataagca	4320
ctgaatcgac	atttgctatg	attatttttg	attaatgaag	gggagggggg	tatggcactg	4380
gaagattttta	agtaggaataa	ggacatgac	tcatccctgg	ctcaggtgga	gggtcggaata	4440
gagaacgggg	agatgaagta	gaaagttaact	accocagctc	agatgagacg	gatgaactct	4500
gaactcaggg	agtggaaagag	gagatgggga	acaggcgatg	gaattggaa	tttattcagg	4560
tcaggatttg	ttaaccattt	gttccgttgg	ttaacagga	acggggggag	ggtagccgca	4620

gggtgaaaa	ggaggcagaa	aggagtgtct	cttccactgc	aggcctcagt	ttctcatct	4680
gtaaaaacgga	gataataatc	cctgtcctgt	cctcctggca	gagttactgt	cagcgtcaaa	4740
cggggaagac	gggtggagg	cacattatag	tttatgaagg	gtcgagaagg	cgggcgggca	4800
gcctcagagt	agggggttat	tatcttccgc	tgcccgcgcg	ccctccccac	gccgggccag	4860
ctggaagtgt	actctgcctg	caggcctcca	aagacttcat	atgctccaga	tctctacttt	4920
ccgcgacccc	tatcacgtgt	gggtaccagg	caacgcgtcg	ctggggggac	acctaacgca	4980
cgtgtcgagg	ggccagacac	ccaacaccac	gatcattcag	ctgcagcctt	tgccaggagcc	5040
cagagactcg	gcgcgcacgc	agagtggcct	cgactcctac	ctgctccagt	tccacggcct	5100
cgtgcgcctg	gtgcaccagg	agcggaacct	ggcctgtgag	taggcggcgca	cgggggcgcg	5160
ggctcggggc	gggctagtgg	gggcggggcc	tggcgggtgg	gggcggggcc	tggcggatgg	5220
agggcgctgt	gggctgtgac	ggaccgggca	gccactggag	ctcggctggg	cctggggcctt	5280
tgaagtattg	tgggtggggg	ctggagagag	cgagttgtcc	ccgctaagaa	agcccgagct	5340
cgggcggtgc	tctgtctggc	ataacctctt	gggatagacc	ctgttggaa	gccctgaac	5400
cgtgacgtcg	aaggtcccca	gaaaactcct	caccctcgcc	ctcacagtcc	tccaactcct	5460
tttcttcata	gatctccgtc	cttcccttcc	cacagccccc	agcacttcc	ccccaccct	5520
ccagccactt	ctcatacaag	ctgatgactt	cgtctttagc	tccactcatg	accggaactc	5580
ttcccccaaa	gaccccaagt	ttctctctca	aagccccact	ccttccccct	cacaaacctca	5640
actctcttct	ctcaactggc	ccaatttctt	ttctcaaaag	accaagcagc	actccgtccc	5700
ccttccccca	ccatcatggc	ctttaattcc	tttctctcct	agtcccccac	ccccaccct	5760
tttttttttt	tttttttttt	tttttttttt	acggagctct	gctctgtcgt	ccaggetgga	5820
gtgcagtggc	gcgactctgg	ctcactgcac	cttccgcctc	cggggtttcc	gcgattctcc	5880
tgctccagcc	tcccaagcag	ctgggactac	aggcacccgc	caccacgccc	ggctaatttt	5940
ttgtattttt	agtagagacg	gggtttccgc	atgttggcca	ggctggtctc	gaactcctga	6000
cctcagcgca	tccacaagcc	tggcctccca	aagtgtctgg	attacaggcg	tgagctgcgc	6060
ccctgcggcc	agcctcaacc	cctgtttttt	tttttaatta	cagttgaaca	aggcttagca	6120
attccttttt	ttcatcacag	tccctggccc	cttctttctt	agcctctaac	aggctaacc	6180
caaaaccctc	ctcacagccc	caggcccttc	tcccatagtt	tccctggtgg	gactctccct	6240
ctctccacag	caactgactct	tgctttctca	tgtttctttc	cccttgggtg	gcctcgcccc	6300
caacctggca	cctctctctg	acagtcocct	gatcctgact	gtctatccac	gattctctgt	6360
accatccgct	gcttctctgg	ctgtgagctg	cctcccgagg	gctctagagc	ccatgtcttc	6420
ttcgaaagtg	ctgtgaaatg	gagctccctt	gtgagtttcc	ggccggagag	agccttgggtg	6480
caggcagaca	cccaggtcac	ctccggagtg	gtcaacttca	cctcgcagca	gctcaatgcc	6540
tacaaccgca	ctcggtatga	actgcgggaa	tctctggagg	acaactgtgt	cgagtatgtg	6600
cagaaacata	tttccgcgga	aaacacgaaa	ggtagatgg	gacggggccc	aggcctgcac	6660
gctgggggca	ggcggggttc	cagacaaatg	gatggacctg	aaggatggat	gcctagagca	6720
acaagaggcc	cacagctggg	ggtttgggac	agaacacacg	cagcttcaagt	cagttggtaa	6780
acgggtccct	ttctctctgg	gcagaaacgc	tttggggttt	gactcaaatc	atggactcct	6840
tggggccctc	tttctcgggc	taactctttg	catgttctgc	agggagccaa	acaaggcgct	6900
cctacacctc	gctggtcctg	ggcgtcctgg	tggcgggttt	catcattgct	gggtgggctg	6960
taggcacatt	cctgtgcaca	ggtggacggc	gatgttaatt	actctccage	cccgtcagaa	7020
ggggctggat	tgatggaggc	tggcaaggga	aagtttcagc	tcactgtgta	ccagactccc	7080
ccaactgaaa	caccagaagg	tttgagtgga	cagctccttt	cttctccccc	atctgccacc	7140
tgaagtattg	agggagggga	gatggagagg	agaggtggac	taagtactgt	gtttgctaag	7200
aaactagaag	cgtgtatgct	tttgtgaatt	agtcgtataa	gtgaatgttt	atctatcttt	7260
gtggaagaac	gataatggag	ttggggcagg	aagcctactc	cccatcctcc	aaagacagac	7320
agaatcacct	gaggcgttca	aaagataata	ccaaataaac	aagtcattcca	caatcaaaat	7380
acaacatcca	atacttccag	gtgtgtcaga	cttgggtgga	gcagctgtga	taatagggta	7440
gaagaagata	acacgaagaa	gtgtgtgaaa	tgtaaaatcc	aagtcataat	gcagtgatca	7500
attatataat	aattaataat	tttctatatt	ttcttatatt	taaggcatgt	ttactctccc	7560
caacttgcac	aatttctgga	aaagtaacct	atacccaatt	cttctgcttc	cttatttctc	7620
actcatctct	tttttttttt	tttttttttt	ttgagacaga	gctctgctct	gttgctagg	7680
ctggagtgca	atggtgtgat	ctcagctcac	tgcaacctct	gctcccggt	tcaagcaatt	7740
ctctcgtctc	agcctcccaa	gcagctggga	ttacagatgc	atgccaccac	accagctaac	7800
ttttgtattt	tttagtagat	atggggtttc	accacttggg	ccatcctggc	ctcgtgatcc	7860
gcctacctgc	gcctccccaa	gtgctgggat	tagacgtgag	ccaactgcgc	tggtcttctc	7920
actcatctct	agaccocagt	caatctgact	ctctcataaa	ctactctaag	atcaccagta	7980
actctcaatt	gtcaaacctg	caccctacat	ggatctcgca	aatttgcgga	ctagaactct	8040
cttttctctg	taactcttga	gataccatcc	ttcaattttt	aaaactgttc	tgtctacttt	8100
ttttcaatcc	ctttgactat	gtcatcttac	acgattcacc	ctggaatgac	tggcttctct	8160
agaatttc						8167

COPY

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 3
gctgaagtgg gcggatcacc

20

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 4
tctagcctgg gtcatgcggc

20

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 5
tcttgccgca tgaccaggc

20

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 6
ggaaggaggc caggagatgg

20

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 7
ctcttactaa gggtagcgcg

20

COPY

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 8
tctgatgccc cacgagacac 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 9
tctctacagg gcaggcagag 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 10
tcgtggtgtt ggtgtctggg 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 11
aggagtgtct cttccactgc 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 12
cttgtatgag aagtggtgg 20

<210> 13

COPY

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 13
cccagacacc aacaccacga t

21

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 14
gtctgtcttt ggaggatggg

20

<210> 15
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 15
agaggtggac aaagtacttg g

21

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 16
ggaagccagc atttccaggg

20

<210> 17
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 17
cctacacttc gctggtcctg ggcgtcctgg tctgc

35

<210> 18
<211> 22

COPY

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 18

caagtacttt gtccacctct cc

22



COPY

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/573,804	FIRST NAMED APPLICANT Martine Aiach	ATTY. DOCKET NO. P08898US00BAS
---	--	-----------------------------------

881
STITES & HARBISON PLLC
1199 NORTH FAIRFAX STREET
SUITE 900
ALEXANDRIA, VA 22314

RECEIVED

FEB 22 2007

STITES & HARBISON PLLC

INTERNATIONAL APPLICATION NO. PCT/IB04/03146	
LA. FILING DATE 09/28/2004	PRIORITY DATE 09/29/2003

CONFIRMATION NO. 9377
371 FORMALITIES LETTER



OC000000022559297

Date Mailed: 02/21/2007

4-21-2007

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 03/28/2006
- Copy of the International Search Report filed on 03/28/2006
- U.S. Basic National Fees filed on 03/28/2006
- Priority Documents filed on 03/28/2006

COPY

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Additional claim fees of **\$360** as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$490** for a Large Entity:

- **\$130** Surcharge.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

- Total additional claim fee(s) for this application is \$ 360

- \$360 for multiple dependent claim surcharge.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sporal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

COPY

COPY

ANITA D JOHNSON

Telephone: (703) 308-9140 EXT 226

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/573,804	PCT/IB04/03146	P08898US00BAS

FORM PCT/DO/EO/905 (371 Formalities Notice)

COPY

COPY

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)	Docket No.	
	1 st Inventor	
	COMPLETE IF KNOWN	
	Appl. No.	
Declaration Submitted with Initial Filing	Filing Date	
Declaration Submitted after Initial Filing		

I hereby declare that:

Each inventor's residence, mailing address and citizenship are as stated below next to their name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Identification of polymorphisms in the EPCR gene associated with thrombotic risk.

the specification of which:

_____ is attached hereto

OR

_____ was filed on September 28, 2004 as PCT International Application No. PCT/B2004/003146
and (if applicable) was amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim FOREIGN PRIORITY benefits under 35 USC 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's certificate(s), or 365(a) of any PCT international application which designated at least one country other than the US, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed. (____ Additional applications listed on supplemental sheet provided herewith)

Prior Foreign Appl. No.	Country	Filing Date (Day/Month/Year)	Priority Not Claimed
03292392.2	EUROPE	29.09.2003	Yes

Power Of Attorney & Correspondence Address Indication

I hereby appoint the practitioners (of Stites & Harblson PLLC) associated with as my/our attorneys or agents to prosecute the application identified above, and to transact all business in the US Patent and Trademark Office connected therewith.

CUSTOMER NUMBER 00881

Please direct all correspondence to the noted Customer Number.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. (____ Additional inventors named on supplemental sheet provided herewith)

SOLE OR FIRST INVENTOR		Citizenship	French
Given Name (First and Middle (if any))		Martine	
Full Mailing Address		70 rue Brancas - 92310 SEVRES - FRANCE	
Residence - City, State/Country (if different from mailing address)		"same as above"	
SIGN AND DATE HERE		Inventor's Signature	Date April 3, 2006
SECOND JOINT INVENTOR (if any)		Citizenship	French
Given Name (First and Middle (if any))		Sophie	
Full Mailing Address		197 rue de Lourmel - 75015 PARIS - FRANCE	
Residence - City, State/Country (if different from mailing address)		"same as above"	
SIGN AND DATE HERE		Inventor's Signature	Date April 3, 2006
THIRD JOINT INVENTOR (if any)		Citizenship	French
Given Name (First and Middle (if any))		Béatrice	
Full Mailing Address		85 avenue du Général Michel Bizot - 75012 PARIS - FRANCE	
Residence - City, State/Country (if different from mailing address)		"same as above"	
SIGN AND DATE HERE		Inventor's Signature	Date April 5, 2006

COPY

Customized PTO/SB/01 (08-03)

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) SUPPLEMENTAL SHEET (use as required)	Docket No.	
	1 st Inventor	
		COMPLETE IF KNOWN
	Serial No.	
	Filing Date	

Additional Prior Foreign Application(s):			
Prior Foreign Appl. No.	Country	Day/Month/Year Filed	Priority Not Claimed

Name Of Additional Joint Inventor, if any		Citizenship	French
Given Name (First and Middle (if any))	Pascale	Family Name or Surname	GAUSSEM
Full Mailing Address	8 rue du Général Castelnau - 94240 L'HAY LES ROSES - FRANCE		
Residence - City, State/Country (if different from mailing address)	"Same as above"		
SIGN AND DATE HERE	Inventor's Signature <i>P. Gaussem</i>	Date	APRIL 5th 2006

Name Of Additional Joint Inventor, if any		Citizenship	French
Given Name (First and Middle (if any))	Joseph	Family Name or Surname	EMMERICH
Full Mailing Address	112 rue Rambuteau - 75001 PARIS - FRANCE		
Residence - City, State/Country (if different from mailing address)	"Same as above"		
SIGN AND DATE HERE	Inventor's Signature <i>J. Emmerich</i>	Date	April 3, 2006

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle (if any))		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle (if any))		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle (if any))		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle (if any))		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

COPY

INFORMATION DISCLOSURE STATEMENT	Application #	10/573,804
	Confirmation #	9377
	Filing Date	03/28/06
	First Inventor	AIACH
	Art Unit	
	Examiner	
	Docket #	P08898US00/BAS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

S I R :

This IDS is submitted pursuant to 37 CFR. §1.97-1.98 and includes the following:


- ☒ A listing of the references on PTO-1449.
- ☒ A copy of all **non-US** references which are listed on the PTO-1449 (US refs not required).
- ☒ A copy of a corresponding foreign **Search Report** which explains the relevance of the references noted therein.
- ☐ A separate **explanation of relevance**.

Please note the following particulars concerning the filing of this IDS:

- ☒ 1. This IDS is filed at whichever is the latest of:
 - within three months of the filing date of a NATIONAL APPLICATION other than a CPA, or
 - within three months of the date of entry into the NATIONAL STAGE as set forth in 37 CFR. §1.491 in an international application, or
 - before the mailing date of a first Office Action on the merits or after filing of an RCE (*but if a first Office Action is mailed but not yet received and the date on the face of the attached foreign communication makes it evident that this IDS is submitted within three months from the mailing of the search report, then applicant is entitled to have this IDS considered under 2.B. below and such boxes should be considered as having been checked*).
 - ☐ 2. This IDS is filed **after a first Office Action**, but before a Final Action, Allowance, or any other action which closes prosecution, and:
 - ☐ A. Is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).
- or
- ☐ B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
 - ☐ C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.
 - ☐ D. An appropriate Statement is attached.

- ☐ 3. This IDS is filed **after** a final action or allowance, but on before payment of the issue fee, and:
- ☐ A. is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).
- and
- ☐ B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- ☐ C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.
- ☐ D. An appropriate Statement is attached.
- ☐ 4. This IDS does not comply with 37 CFR 1.97-1.98, and is being filed **for placement in the file** pursuant to 37 CFR. §1.97(i).
- ☒ 5. It will also be appreciated that:
- a. It is believed that this IDS complies fully with 37 CFR 1.56 and 1.97-98 and with MPEP § 609; but if for some reason it does not and will not be entered, the examiner is requested to telephone the undersigned so that any deficiency can be timely remedied.
- b. Some of the documents may have markings thereon, but no significance should be attached to those markings.
- c. These documents are not necessarily analogous art.
- d. Where an English language translation of an abstract is provided from a public source, applicant cannot vouch for the accuracy of that translation.
- ☒ 6. If no payment is enclosed and a fee is due in connection with this communication or if the payment enclosed is insufficient, the Director is authorized to charge any fee or additional fee due with this communication to Deposit Account No. 12-0555.

Respectfully submitted,


By: B. Aaron Schulman
Registration No.: 31,877

Date: May 21, 2007

STITES & HARBISON PLLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314
TEL: 703-739-4900 • FAX: 703-739-9577 • CUSTOMER NO. 00881

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application #	10/573,804
	Confirmation #	9377
	Filing Date	03/28/06
	First Inventor	AIACH
	Art Unit	
	Examiner	
Sheet 1 of 1	Docket #	P08898US00/BAS

U.S. PATENT DOCUMENTS

Exam. Initial*	Document No. Number - Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.
	US-			

FOREIGN PATENT DOCUMENTS

Exam. Initial*	Country-Number-Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.	Translation

NON PATENT LITERATURE DOCUMENTS

Exam. Initial*	Include NAME of the author (in CAPS), Title of Article/Item, Date, Page(s), Volume-Issue No., Publisher, City and/or Country where published	Translation
	HAYASHI et al, "Organization and chromosomal localization of the human endothelial protein C receptor gene." Oct. 1, 1999, pp. 367-373, vol. 238, no. 2	
	ESPANA et al, "A new polymorphism in the 3' UTR region of the endothelial protein C receptor associated with increased levels of circulating activated protein C and decreased risk of venous thrombosis", 2001, pg. 0C885, Thromb. Haemost.	
	MEDINA et al, "the 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene is associated with levels of soluble plasma EPCR", July 2003, p. P0026, vol. 1	
	DATABASE SNP "Online! NCBI: database accession no. RS2069945	
	DATABASE SNP "Online! NCBI: database accession no. RS867186	
	DATABASE SNP "Online! NCBI: database accession no. RS2069944	
	DATABASE SNP "Online! NCBI: database accession no. RS2069948	
	DATABASE SNP "Online! NCBI: database accession no. RS945960	
	DATABASE SNP "Online! NCBI: database accession no. RS2069950	
	DATABASE SNP "Online! NCBI: database accession no. RS9574	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* Examiner: Initial if considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PTO STAMPED RECEIPT	Application #	10/573,804
	Confirmation #	9377
	Filing Date	03/28/06
	First Inventor	AIACH
	Art Unit	
	Examiner	
	Docket #	P08898US00/BAS

PAPERS SUBMITTED

COPY

- | | |
|---|--|
| <input type="checkbox"/> Transmittal Form
<input checked="" type="checkbox"/> Amendment
<input checked="" type="checkbox"/> with Attachments
<input type="checkbox"/> Amendment/Response After Final
<input type="checkbox"/> with Attachments
<input checked="" type="checkbox"/> Petition for Extension of Time
<input checked="" type="checkbox"/> Response to Missing Parts
<input checked="" type="checkbox"/> Declaration
<input type="checkbox"/> Translation of Application
<input type="checkbox"/> Assignment
<input type="checkbox"/> Priority Document
<input checked="" type="checkbox"/> Fee of \$250 (CREDIT CARD - PTO-2038)
<input checked="" type="checkbox"/> Copy of Notice
<input type="checkbox"/> | <input checked="" type="checkbox"/> IDS: Including
<input checked="" type="checkbox"/> List of References
<input checked="" type="checkbox"/> Search Report
10 Refs. Transmitted
<input type="checkbox"/> Statement of Relevance
<input type="checkbox"/> Issue Fee Transmittal
<input type="checkbox"/> Publication Fee Transmittal
<input type="checkbox"/> Letter to Draftsman
sheets of formal drawings
(figs.)
<input type="checkbox"/> Notice of Appeal
<input type="checkbox"/> Appeal Brief
<input type="checkbox"/>
<input type="checkbox"/> |
|---|--|

PTO Receipt Stamp →

